source
- Hikma invests $267 million in Ohio as Cingulate receives CRL for ADHD candidateHikma Pharmaceuticals, a generic drugmaker, announced a $267 million investment to expand its manufacturing footprint in Ohio. The plan includes $216 million to upgrade its existing Columbus plant…
- Novo Holdings invests €500 million in Europe-focused fund as Alnylam advances second obesity drug to clinicNovo Holdings, the investment arm of the Novo Nordisk Foundation, has committed €500 million to the Scaleup Europe Fund, a vehicle aimed at supporting European biotech scale‑ups. Alnylam Pharmaceu…